Mestag focuses on fibroblast-immune interactions to develop innovative new treatments for inflammatory disease and cancer. Through our unique understanding of fibroblast immunology, we are advancing a pipeline of first-in-class antibody programs and targets for new treatments. Backed by committed leading global investors, world-class founders and a highly experienced leadership team, Mestag offers an exciting, diverse and balanced place to work, with competitive benefits, generous vacation time and the room to grow and develop your career. Show more Show less
$2M sweet spot round size
2020
$2M
from 1 investors over 1 rounds
Mestag Therapeutics raised $2M on September 28, 2024
Investors: Innovate UK